BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novo Nordisk A/S (NVO) Gets Green Light for Tresiba in EU


1/22/2013 7:03:03 AM

The European Commission has issued clearance to market Novo Nordisk's diabetes therapies, Tresiba and Ryzodeg, across 27 European Union (EU) states. Novo Nordisk anticipates launching Tresiba, brand name of insulin degludec, in the UK and Denmark during the first six months of 2013 and in other states all through 2013 and 2014. The company will offer Tresiba in two concentrations with 80 and 160 units per injection doses. Another insulin Ryzodeg, the brand name for insulin degludec/insulin aspart, will be introduced a year after Tresiba launch. Both the products will be made available in FlexTouch prefilled insulin pen. Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen said the marketing authorizations are the important mile stones for the company and diabetes treatment.


   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES